487 related articles for article (PubMed ID: 25081988)
1. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
Wang CH; Lin JC; Lin HA; Chang FY; Wang NC; Chiu SK; Lin TY; Yang YS; Kan LP; Yang CH; Chan MC; Yeh KM
J Microbiol Immunol Infect; 2016 Jun; 49(3):378-86. PubMed ID: 25081988
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for hospital acquisition of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia in adults: A matched case-control study.
Wang CH; Lin JC; Chang FY; Yu CM; Lin WS; Yeh KM
J Microbiol Immunol Infect; 2017 Oct; 50(5):646-652. PubMed ID: 28688829
[TBL] [Abstract][Full Text] [Related]
3. Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial
Hevia EC; Wooten L; Carr AL
Ann Pharmacother; 2024 Jul; 58(7):698-704. PubMed ID: 37776160
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.
Lai CH; Chi CY; Chen HP; Chen TL; Lai CJ; Fung CP; Yu KW; Wong WW; Liu CY
J Microbiol Immunol Infect; 2004 Dec; 37(6):350-8. PubMed ID: 15599467
[TBL] [Abstract][Full Text] [Related]
5. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M
J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico.
Herrera-Heredia SA; Pezina-Cantú C; Garza-González E; Bocanegra-Ibarias P; Mendoza-Olazarán S; Morfín-Otero R; Camacho-Ortiz A; Villarreal-Treviño L; Rodríguez-Noriega E; Paláu-Davila L; Maldonado-Garza HJ; Flores-Treviño S
J Med Microbiol; 2017 Aug; 66(8):1102-1109. PubMed ID: 28771141
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals.
Tsiodras S; Pittet D; Carmeli Y; Eliopoulos G; Boucher H; Harbarth S
Scand J Infect Dis; 2000; 32(6):651-6. PubMed ID: 11200376
[TBL] [Abstract][Full Text] [Related]
8. Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole.
Yilmaz M; Celik AF; Mert A
J Infect Chemother; 2007 Apr; 13(2):122-3. PubMed ID: 17458682
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains.
Kim EJ; Kim YC; Ahn JY; Jeong SJ; Ku NS; Choi JY; Yeom JS; Song YG
BMC Infect Dis; 2019 Aug; 19(1):754. PubMed ID: 31462215
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.
Nys C; Cherabuddi K; Venugopalan V; Klinker KP
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427300
[No Abstract] [Full Text] [Related]
11. Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.
Araoka H; Baba M; Okada C; Abe M; Kimura M; Yoneyama A
Int J Infect Dis; 2017 May; 58():18-21. PubMed ID: 28257816
[TBL] [Abstract][Full Text] [Related]
12. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.
Cho SY; Lee DG; Choi SM; Park C; Chun HS; Park YJ; Choi JK; Lee HJ; Park SH; Choi JH; Yoo JH
BMC Infect Dis; 2015 Feb; 15():69. PubMed ID: 25887489
[TBL] [Abstract][Full Text] [Related]
13. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.
Al-Jasser AM
Ann Clin Microbiol Antimicrob; 2006 Sep; 5():23. PubMed ID: 16978420
[TBL] [Abstract][Full Text] [Related]
14. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?
Cho SY; Kang CI; Kim J; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2014; 58(1):581-3. PubMed ID: 24126583
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
Hand E; Davis H; Kim T; Duhon B
J Antimicrob Chemother; 2016 Apr; 71(4):1071-5. PubMed ID: 26801080
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for death from Stenotrophomonas maltophilia bacteremia.
Osawa K; Shigemura K; Kitagawa K; Tokimatsu I; Fujisawa M
J Infect Chemother; 2018 Aug; 24(8):632-636. PubMed ID: 29673561
[TBL] [Abstract][Full Text] [Related]
18. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.
Velázquez-Acosta C; Zarco-Márquez S; Jiménez-Andrade MC; Volkow-Fernández P; Cornejo-Juárez P
Support Care Cancer; 2018 Jun; 26(6):1953-1960. PubMed ID: 29307014
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
Junco SJ; Bowman MC; Turner RB
Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
[TBL] [Abstract][Full Text] [Related]
20. Increase in the Prevalence of Resistance Determinants to Trimethoprim/Sulfamethoxazole in Clinical Stenotrophomonas maltophilia Isolates in China.
Hu LF; Chen GS; Kong QX; Gao LP; Chen X; Ye Y; Li JB
PLoS One; 2016; 11(6):e0157693. PubMed ID: 27310255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
